GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the closing of its ...
On behalf of our team, we'd like to thank everyone for joining us today for the presentation of ProPhase Labs for the Third Quarter 2024 Results. ProPhase is trading on the NASDAQ under the ticker ...
Jed Latkin to transition to CEOWARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- , Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and ...
As of November 19, 2024, ProPhase Labs, Inc. had a $18.1 million market capitalization, putting it in the 10th percentile of companies in the Pharmaceuticals industry. ProPhase Labs, Inc. does not ...
ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase” or the "Company”), a next-generation biotech, genomics and diagnostics company, today announced the ...